INCHEON, South Korea, Aug. 6, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) ...

With the newly approved indication for CRS, Avtozma IV now aligns with all approved indications for Actemra IV. CRS is a life-threatening condition in which an overactive immune response leads to the ...

The transition from preclinical development to clinical trials is a critical, yet high-risk stage in drug development, with approximately 89% of drugs failing to progress through all phases of ...

The prevalence of serious inflammatory safety issues such as cytokine release syndrome and immune effector cell–associated ...

CytoAgents Inc. completed the dose-limiting toxicity observation for the first cohort in a trial targeting CRS in blood cancer patients. The Safety Review Committee approved dose escalation for the ...

The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...

The chimeric antigen receptor (CAR) T cell therapy anitocabtagene autoleucel (anito-cel) continued to show strong results in treating relapsed/refractory multiple myeloma, according to new trial data ...

Credit: Celltrion CRS is a life-threatening condition that results in the excessive release of cytokines into the bloodstream, causing inflammation and damage to organs and tissues. With the newly ...